Physician profile
Matthew R Ricks
NPI 1669403861
$10,702.27
in general payments reported to CMS, 2019-2025
25 companies · $2,817 in 2025
The $2,817 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $1,751 · 2021: $612 · 2022: $515 · 2023: $2,302 · 2024: $1,672 · 2025: $2,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,343 · Food and Beverage: $448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,343.25 |
| Food and Beverage | $447.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,141.54 | 2019-2025 | |
| Allergan, INC. | $1,811.02 | 2019-2022 | |
| Janssen Biotech, INC. | $236.23 | 2019-2022 | |
| Genentech USA, INC. | $200.03 | 2019-2020 | |
| Lilly USA, LLC | $194.91 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $173.15 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $113.95 | 2019-2023 | |
| Pfizer INC. | $102.06 | 2019-2021 | |
| Organogenesis INC. | $93.56 | 2020-2023 | Puraply |
| Prugen, INC. Pharmaceuticals | $89.34 | 2019 | |
| Genzyme Corporation | $88.92 | 2019-2021 | |
| Leo Pharma INC. | $84.62 | 2019-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $74.10 | 2019-2020 | |
| Incyte Corporation | $43.39 | 2021-2024 | Opzelura |
| Mayne Pharma Commercial LLC | $38.48 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $32.94 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $31.62 | 2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $28.71 | 2020 | |
| Celgene Corporation | $27.84 | 2019 | |
| Galderma Laboratories, L.P. | $26.95 | 2019 | |
| Vyne Pharmaceuticals INC. | $15.42 | 2021 | |
| Almirall LLC | $14.60 | 2021 | |
| Amgen INC. | $14.01 | 2021 | |
| Dermira, INC. | $13.97 | 2019 | |
| Tactile Systems Technology INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ricks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.